| Literature DB >> 31466831 |
K Abboud1, T André2, M Brunel3, M Ducreux4, C Eveno5, O Glehen6, D Goéré7, J-M Gornet8, J H Lefevre9, P Mariani10, A Pinto11, F Quenet12, O Sgarbura12, M Ychou13, M Pocard14.
Abstract
When peritoneal metastases are diagnosed (strong agreement of experts): (i) seek advice from a multidisciplinary coordination meeting (MCM) with large experience in peritoneal disease (e.g. BIG RENAPE network); (ii) transfer (or not) the patient to a referral center with experience in hyperthermic intraperitoneal chemotherapy (HIPEC), according to the advice of the MCM. With regard to systemic chemotherapy (strong agreement of experts): (i) it should be performed both before and after surgery, (ii) for no longer than 6 months; (iii) without postoperative anti-angiogenetic drugs. With regard to cytoreductive surgery (strong agreement of experts): (i) Radical surgery requires a xiphopubic midline incision; (ii) no cytoreductive surgery via laparoscopy. With regard to HIPEC: HIPEC can be proposed for trials outside an HIPEC referral center (weak agreement between experts): (i) if surgery is radical; (ii) if the expected morbidity is "reasonable"; (iii) if the indication for HIPEC was suggested by a MCM, and; (iv) mitomycin is preferred to oxaliplatin (which cannot be recommended) for this indication.Entities:
Keywords: Carcinomatosis; Colon cancer; Cytoreductive surgery; HIPEC
Year: 2019 PMID: 31466831 DOI: 10.1016/j.jviscsurg.2019.08.002
Source DB: PubMed Journal: J Visc Surg ISSN: 1878-7886 Impact factor: 2.043